However, given that siRNA‐induced suppression of FXYD3 in breast cancer cells that overexpress FXYD3 amplifies effects of doxorubicin or γ‐radiation on cell death and apoptosis, overexpression of FXYD3 is a potentially useful treatment target [28]. Here, FXYD3 is linked to breast carcinoma.